See more : Ribo Fashion Group Co., Ltd. (603196.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Guardant Health, Inc. (GH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardant Health, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Shree Minerals Limited (SHH.AX) Income Statement Analysis – Financial Results
- Pick n Pay Stores Limited (PKPYY) Income Statement Analysis – Financial Results
- Systems Design Co., Ltd. (3766.T) Income Statement Analysis – Financial Results
- Prajay Engineers Syndicate Limited (PRAENG.NS) Income Statement Analysis – Financial Results
- Semperit Aktiengesellschaft Holding (SEIGY) Income Statement Analysis – Financial Results
Guardant Health, Inc. (GH)
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 563.95M | 449.54M | 373.65M | 286.73M | 214.38M | 90.64M | 49.84M | 25.25M |
| Cost of Revenue | 227.05M | 156.33M | 122.91M | 92.54M | 70.72M | 43.21M | 31.62M | 22.12M |
| Gross Profit | 336.90M | 293.21M | 250.74M | 194.20M | 143.66M | 47.43M | 18.22M | 3.13M |
| Gross Profit Ratio | 59.74% | 65.23% | 67.11% | 67.73% | 67.01% | 52.33% | 36.56% | 12.38% |
| Research & Development | 367.19M | 373.81M | 263.22M | 149.86M | 86.29M | 50.71M | 25.56M | 10.86M |
| General & Administrative | 155.80M | 163.96M | 206.64M | 192.77M | 61.40M | 36.19M | 36.78M | 9.92M |
| Selling & Marketing | 295.23M | 299.83M | 191.88M | 106.51M | 78.34M | 53.47M | 32.50M | 26.19M |
| SG&A | 451.03M | 463.78M | 398.52M | 299.28M | 139.73M | 89.66M | 69.27M | 36.11M |
| Other Expenses | 83.40M | -112.56M | 25.18M | 3.64M | 88.00K | 4.70M | -1.06M | -1.00K |
| Operating Expenses | 901.62M | 837.59M | 661.74M | 449.15M | 226.03M | 140.37M | 94.84M | 46.97M |
| Cost & Expenses | 1.13B | 993.92M | 784.65M | 541.68M | 296.75M | 183.58M | 126.45M | 69.10M |
| Interest Income | 35.37M | 6.07M | 3.93M | 10.17M | 13.74M | 5.27M | 2.23M | 733.00K |
| Interest Expense | 2.58M | 2.58M | 2.58M | 4.77M | 1.18M | 1.25M | 2.70M | 3.02M |
| Depreciation & Amortization | 42.88M | 35.96M | 22.27M | 16.07M | 13.61M | 7.14M | 5.21M | 3.69M |
| EBITDA | -433.31M | -614.91M | -359.62M | -225.07M | -54.93M | -75.84M | -75.31M | -39.42M |
| EBITDA Ratio | -76.83% | -144.79% | -102.21% | -84.10% | -31.97% | -91.54% | -140.91% | -156.13% |
| Operating Income | -564.73M | -544.38M | -411.00M | -254.95M | -82.37M | -92.94M | -76.61M | -43.85M |
| Operating Income Ratio | -100.14% | -121.10% | -110.00% | -88.92% | -38.42% | -102.54% | -153.71% | -173.66% |
| Total Other Income/Expenses | 85.96M | -109.07M | 26.53M | 9.05M | 12.65M | 8.72M | -6.60M | -2.29M |
| Income Before Tax | -478.76M | -653.45M | -384.47M | -245.90M | -69.72M | -84.23M | -83.21M | -46.13M |
| Income Before Tax Ratio | -84.90% | -145.36% | -102.89% | -85.76% | -32.52% | -92.92% | -166.96% | -182.71% |
| Income Tax Expense | 685.00K | 1.14M | 300.00K | 379.00K | -1.87M | 38.00K | 7.00K | 6.00K |
| Net Income | -479.45M | -654.59M | -384.77M | -246.28M | -67.85M | -85.06M | -83.22M | -46.14M |
| Net Income Ratio | -85.02% | -145.61% | -102.98% | -85.89% | -31.65% | -93.85% | -166.97% | -182.74% |
| EPS | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| EPS Diluted | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| Weighted Avg Shares Out | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
| Weighted Avg Shares Out (Dil) | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Guardant Health shares slide as colon cancer test is set for FDA advisory committee review
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports